GenFleet Therapeutics Announces Promising Clinical Data for GFH375 at 2026 ASCO: Significant Progress in KRAS G12D-Mutant Cancer Treatment
Key Highlights
- GFH375, an oral KRAS G12D inhibitor, demonstrated significant efficacy in treating cholangiocarcinoma (CCA) and colorectal cancer (CRC) patients.
- Clinical data presented at the 2026 ASCO Annual Meeting show a 40% overall response rate (ORR) and 95% disease control rate (DCR) in CCA patients, with even higher efficacy at the recommended phase II dose (RP2D).
- GFH375 is the first KRAS G12D inhibitor to advance to phase III for metastatic pancreatic cancer globally and has received two Breakthrough Therapy Designations in China.
- Strategic partnership with Verastem provides global commercialization opportunities, excluding China.
- Manageable safety profile with no new safety signals reported.
- Ongoing studies evaluating combination therapies, with more results expected at upcoming conferences.
Detailed Report
GenFleet Therapeutics (Shanghai) Inc. (“GenFleet”, Stock Code: 2595) has announced updated and highly promising clinical data for its lead program, GFH375, an oral KRAS G12D inhibitor, at the prestigious 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Clinical Data Highlights
- Cholangiocarcinoma (CCA):
- Among 20 heavily pretreated patients with KRAS G12D-mutant CCA (85% at stage IV, 75% received ≥2 prior lines of therapy, 85% previously on immunotherapy), GFH375 achieved a remarkable 40% overall response rate (ORR) and a 95% disease control rate (DCR) across all dose levels.
- At the recommended phase II dose (600 mg QD), 18 patients achieved an ORR of 44.4% and DCR of 94.4%.
- The median progression-free survival (mPFS) was 6.2 months; median overall survival (mOS) was not reached at cutoff.
- Target lesion shrinkage was observed in 18 patients, with 40% achieving at least 30% reduction and one complete response.
- Colorectal Cancer (CRC):
- For 41 advanced CRC patients (95.1% received ≥2 prior therapies), the mPFS was 4.1 months and mOS was 10.3 months.
- Of 35 evaluable CRC patients, 27 (77%) achieved stable disease or partial response, with 11% showing ≥30% tumor reduction.
- Preliminary data support further investigation of GFH375 in combinational regimens; a phase Ib/II trial with cetuximab for CRC and other solid tumors is ongoing, with more data forthcoming.
- Safety Profile:
- GFH375 showed a manageable and favorable safety/tolerability profile in both CCA and CRC, with a mean relative dose intensity of 98.5%.
- The most common treatment-related adverse events (TRAEs) were grade 1-2 and included diarrhea, nausea, vomiting, anemia, and increased AST. All were manageable with supportive care.
- No new safety signals observed compared to previous trials.
Strategic and Regulatory Milestones
- GFH375 is the world’s first oral KRAS G12D inhibitor to advance to phase III trials for metastatic pancreatic cancer.
- It is the first in China to receive two Breakthrough Therapy Designations for monotherapy in G12D-mutant pancreatic cancer and non-small cell lung cancer.
- GenFleet’s collaboration with Verastem grants Verastem exclusive development and commercialization rights outside of China, while GenFleet retains rights in China—a potential significant source of future revenue and global market expansion.
- Verastem exercised the license for GFH375/VS-7375 in January 2025, marking the first license from this collaboration.
Potential Impact for Shareholders
- The robust efficacy and manageable safety profile in hard-to-treat KRAS G12D-mutant tumors position GFH375 as a potential new standard of care, especially in CCA and CRC, both considered areas of high unmet medical need.
- The ongoing global and China-specific development, regulatory progress, and commercial partnerships could be highly price-sensitive and may drive significant shareholder value if milestones are achieved.
- The upcoming data from combination therapy studies and further regulatory achievements could serve as additional catalysts for the stock.
Management Commentary
“This is the fourth consecutive selection of GFH375’s clinical data for oral presentations at top-tier global academic conferences, including ASCO, ESMO, and WCLC. We are encouraged by its therapeutic potential in diverse tumor types and look forward to more positive results from subsequent monotherapy and combinational investigations.”
— Yu Wang, M.D., Ph.D., Chief Medical Officer, GenFleet
Technical Glossary (Abbreviated)
- KRAS: Kirsten RAS, a key oncogene family
- mPFS: Median progression-free survival
- mOS: Median overall survival
- ORR: Overall response rate
- DCR: Disease control rate
- TRAEs: Treatment-related adverse events
- TEAEs: Treatment-emergent adverse events
- QD: Once daily
- RP2D: Recommended phase II dose
Conclusion
The newly announced data on GFH375 offer strong evidence of its potential as a best-in-class therapy for KRAS G12D-mutant cancers and highlight the company’s leadership in this field. Investors should monitor further trial readouts, regulatory updates, and partnership developments closely, as these could have a major impact on GenFleet’s valuation and share price.
Disclaimer
The information above contains forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from current expectations. Investors are advised to conduct their own research and consult the company’s official disclosures before making investment decisions. Neither the author nor GenFleet Therapeutics is liable for any losses incurred from acting on this information.
【粵語版】勁方醫藥公佈GFH375於2026年ASCO臨床數據：KRAS G12D突變腫瘤治療現突破性進展
重點摘要
- GFH375作為口服KRAS G12D抑制劑，於膽管癌（CCA）及結直腸癌（CRC）患者中展現顯著療效。
- 2026年ASCO年會臨床數據顯示，CCA患者總反應率(ORR)達40%，疾病控制率(DCR)高達95%，推薦二期劑量下療效更佳。
- GFH375為全球首個進入III期轉移性胰腺癌研究的KRAS G12D抑制劑，並已獲中國兩項突破性療法認定。
- 與Verastem的戰略合作，提供中國以外地區的全球商業化機會。
- 安全性良好，未見新不良反應訊號。
- 現正進行組合療法研究，更多數據將於未來學術會議發表。
詳細報導
勁方醫藥科技（上海）股份有限公司（「勁方醫藥」，股份代碼：2595）於2026年美國臨床腫瘤學會（ASCO）年會發佈其主打產品GFH375（口服KRAS G12D抑制劑）最新臨床數據，表現備受市場矚目。
臨床數據重點
- 膽管癌（CCA）：
- 20名KRAS G12D突變CCA患者中，85%屬IV期，75%接受過兩線或以上治療，85%曾接受免疫治療。
- 總反應率（ORR）達40%，疾病控制率（DCR）95%。在推薦二期劑量（600mg QD）下，ORR提升至44.4%，DCR為94.4%。
- 中位無惡化生存期（mPFS）為6.2個月，中位總生存期（mOS）於數據截止時尚未達到。
- 18名患者腫瘤明顯縮小，40%病人腫瘤縮小超過30%，其中一例完全緩解。
- 結直腸癌（CRC）：
- 41名晚期CRC患者（95.1%接受過兩線或以上治療），mPFS為4.1個月，mOS為10.3個月。
- 35名評估患者中，27人（77%）達到疾病穩定或部分緩解，11%患者腫瘤縮小超過30%。
- 現正開展與西妥昔單抗聯合治療的Ib/II期試驗，進一步數據有望在未來發佈。
- 安全性：
- GFH375在CCA及CRC患者中展現良好安全、耐受性，平均相對劑量強度98.5%。
- 最常見治療相關不良事件（TRAEs）為1-2級，包括腹瀉、噁心、嘔吐、貧血及AST升高，均可經支持性治療恢復。
- 未見新安全訊號出現。
戰略及監管里程碑
- GFH375為全球首個口服KRAS G12D抑制劑進入III期胰腺癌臨床。
- 亦為中國首款獲「突破性療法」認定的KRAS G12D抑制劑，適用於G12D突變胰腺癌及非小細胞肺癌。
- 與Verastem合作，授予其中國以外開發及商業化權利，勁方醫藥保留中國區權益，具潛在巨大利潤及全球市場拓展空間。
- Verastem已於2025年一月行使GFH375/VS-7375許可，為合作首個獲授權項目。
對股東的潛在影響
- 療效強勁且安全性佳，GFH375有望成為KRAS G12D突變腫瘤新標準治療方案，特別是CCA及CRC等高未被滿足醫療需求領域。
- 持續的臨床開發、監管推進及全球合作屬高度敏感信息，若里程碑順利，有望大幅提升公司估值及股東回報。
- 聯合療法及進一步監管進展將成為潛在股價催化劑，建議密切關注公司後續公告。
管理層評論
「這是GFH375臨床數據連續第四次獲ASCO、ESMO及WCLC等全球頂級學術會議口頭報告。我們對其多腫瘤適應症潛力充滿信心，期待後續單藥及聯合療法帶來更多正面成果。」
—— 勁方醫藥首席醫學官 王宇博士
術語簡介
- KRAS： 癌基因家族
- mPFS： 中位無惡化生存期
- mOS： 中位總生存期
- ORR： 總反應率
- DCR： 疾病控制率
- TRAEs： 治療相關不良事件
- TEAEs： 治療過程中新發不良事件
- QD： 每日一次
- RP2D： 推薦二期劑量
總結
GFH375的最新臨床數據顯示其有望成為KRAS G12D突變腫瘤治療領域的領先藥物。建議投資者密切留意後續試驗結果、監管進展及合作動態，這些均具潛在股價影響力。
免責聲明
本文包含前瞻性聲明，存在不確定因素，最終結果或與預期不同。投資者應自行查閱公司正式公告，審慎決定，作者及勁方醫藥概不負責任何損失。
